NO943749L - Sammensetning for profylakse og behandling av myopi - Google Patents

Sammensetning for profylakse og behandling av myopi

Info

Publication number
NO943749L
NO943749L NO943749A NO943749A NO943749L NO 943749 L NO943749 L NO 943749L NO 943749 A NO943749 A NO 943749A NO 943749 A NO943749 A NO 943749A NO 943749 L NO943749 L NO 943749L
Authority
NO
Norway
Prior art keywords
treatment
prophylaxis
myopl
composition
myopia
Prior art date
Application number
NO943749A
Other languages
English (en)
Other versions
NO943749D0 (no
Inventor
Toshiro Shigemitsu
Noriko Watanabe
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Publication of NO943749D0 publication Critical patent/NO943749D0/no
Publication of NO943749L publication Critical patent/NO943749L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En forbindelse for profylakse og behandling av myopl omfattende en forbindelse med formelen hvor R er en alkyl, R1 er et hydrogen eller en amlno og R2 er en karboksyl eller et tetrazol, eller et salt derav. Sammensetningen for profylakse og behandling av myopl Ifølge foreliggende oppfinnelse viser Ikke kun relakserende virkning på clllar glatt muskel l kanin, men viser også overlegne effekter for forhindring og behandling av myopl l pasienter på hvilke mydrln-M, et konvensjonelt preparat for profylakse og behandling av myopl, Ikke har noen effekt. I tillegg viser sammen- setningen Ingen mydrlatlsk respons og kan med fordel bil benyttet for profylakse og behandling av myopl.
NO943749A 1993-10-07 1994-10-06 Sammensetning for profylakse og behandling av myopi NO943749L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25138393 1993-10-07
JP1253794 1994-02-04

Publications (2)

Publication Number Publication Date
NO943749D0 NO943749D0 (no) 1994-10-06
NO943749L true NO943749L (no) 1995-04-10

Family

ID=26348167

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943749A NO943749L (no) 1993-10-07 1994-10-06 Sammensetning for profylakse og behandling av myopi

Country Status (18)

Country Link
US (1) US5519030A (no)
EP (1) EP0647445B1 (no)
KR (1) KR100193406B1 (no)
CN (1) CN1108095A (no)
AT (1) ATE175350T1 (no)
AU (1) AU677860B2 (no)
BR (1) BR9404007A (no)
CA (1) CA2133805A1 (no)
CZ (1) CZ244994A3 (no)
DE (1) DE69415757T2 (no)
ES (1) ES2126039T3 (no)
FI (1) FI944687L (no)
HU (1) HUT71112A (no)
NO (1) NO943749L (no)
NZ (1) NZ264616A (no)
PL (1) PL305352A1 (no)
SK (1) SK121394A3 (no)
TW (1) TW282471B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952338A (en) * 1996-07-05 1999-09-14 Takeda Chemical Industries, Ltd. Agent for prophylaxis and treatment of disturbance of visual function
SE0002211D0 (sv) * 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
MD38Z5 (ro) * 2009-02-20 2010-02-28 Татьяна ГИДИРИМСКИЙ Metodă de corecţie a vederii la slab văzători
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
JPH06110587A (ja) * 1992-09-28 1994-04-22 Omron Corp 自動取引き機の電源制御方法とその装置

Also Published As

Publication number Publication date
FI944687A0 (fi) 1994-10-06
KR100193406B1 (ko) 1999-06-15
CN1108095A (zh) 1995-09-13
ES2126039T3 (es) 1999-03-16
HU9402883D0 (en) 1995-01-30
FI944687A7 (fi) 1995-04-08
SK121394A3 (en) 1995-07-11
PL305352A1 (en) 1995-04-18
DE69415757T2 (de) 1999-06-10
US5519030A (en) 1996-05-21
TW282471B (no) 1996-08-01
EP0647445A1 (en) 1995-04-12
CZ244994A3 (en) 1995-04-12
KR950010896A (ko) 1995-05-15
ATE175350T1 (de) 1999-01-15
NZ264616A (en) 1997-06-24
HUT71112A (en) 1995-11-28
DE69415757D1 (de) 1999-02-18
AU677860B2 (en) 1997-05-08
BR9404007A (pt) 1995-06-13
EP0647445B1 (en) 1999-01-07
FI944687L (fi) 1995-04-08
CA2133805A1 (en) 1995-04-08
NO943749D0 (no) 1994-10-06
AU7441794A (en) 1995-04-27

Similar Documents

Publication Publication Date Title
NO952309L (no) Anvendelse av riluzol ved behandling av Parkinsons sykdom og Parkinsonske syndromer
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
NO953370L (no) Anvendelse av riluzol ved behandling av neuro-AIDS
FI972781A7 (fi) Deskarboetoksiloratadiinin (DCL) tai sen farmaseuttisesti hyväksyttävän suolan käyttö valmistettaessa farmaseuttista tuotetta
NO307645B1 (no) Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat
ATE150308T1 (de) Hemmung von thrombin
DE69418601D1 (de) Guanidinderivate mit therapeutischer wirkung
DE69719931D1 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
DE69331546D1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
DK0583271T3 (da) Arylmorpholin, fremstilling og anvendelse
NO943749D0 (no) Sammensetning for profylakse og behandling av myopia
FI895012A0 (fi) Laekemedel innehaollande nitroxialkylaminer med amidfunktion samt foerfarande foer framstaellning av naemnda foereningar.
DE69400704D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
ID21755A (id) Antijamur azol yang mengandung ester asam amino
KR950016720A (ko) 아밀로이드 단백질의 효과를 저해하는 방법
NO305799B1 (no) Nye kinolinderivater, farmas°ytiske preparater inneholdende slike derivater, deres anvendelse samt mellomprodukter
ATE145135T1 (de) Verwendung von riluzol zum schutz gegen strahlenschäden
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
MY110416A (en) Composition for the treatment of schizophrenia.